Researchers at Hitgen Ltd. and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. have identified proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1) targeting moiety via linker.
Itabmed Ltd. received an IND approval to start a phase I trial of its CD3-activating bispecific antibody A-337 for the treatment of patients with advanced solid tumors.
Although advances in chemotherapy have dramatically improved outcomes for children with leukemia, patients with high-risk and aggressive cancers require intense drug regimens that push safety limits. Researchers have formulated an antibody guidance system in mice that could empower chemotherapy against childhood leukemias while minimizing drug toxicity.
By combining drug sensitivity with genomic profiling of tumor cells, a study from St. Jude Children's Research Hospital with more than 800 patients has shown a wide diversity in drug sensitivity for pediatric acute lymphoblastic leukemia (ALL) and defined six patterns of response to treatment. “This work provides a framework for ‘functional precision medicine’,” corresponding author Jun Yang, vice chair of the Department of Pharmacy and Pharmaceutical Sciences at St. Jude Children's Research Hospital, told BioWorld.
Researchers from Hangzhou Healzen Therapeutics Co. Ltd. and Biopolar Hongye (Nantong) Pharmaceutical Co. Ltd. presented the discovery and preclinical characterization of a next-generation Bcl-2 inhibitor, HZ-L105, being developed for the treatment of hematological cancers.
The Dana-Farber Cancer Institute has identified molecular glue degraders comprising a cereblon (CRBN) ubiquitin ligase-binding moiety covalently bound to a zinc finger protein Helios (IKZF2) ligand reported to be useful for the treatment of cancer.
Innocare Pharma Ltd. has received IND approval from China's National Medical Products Administration (NMPA) to begin clinical trials of its B-cell lymphoma-2 (BCL2) inhibitor ICP-248.
After a shaky start to the year, Autolus Therapeutics plc has revived its fortunes, with Blackstone Life Sciences investing up to $250 million to fund its CAR T-cell technology and lead product targeting acute lymphoblastic leukemia.
Just months after Jazz Pharmaceuticals plc's inventory of a therapy key to treating certain acute lymphoblastic leukemia and lymphoblastic lymphoma patients appears to have run out, FDA approval has arrived for an alternative: a recombinant version of the medicine the company developed, Rylaze (asparaginase Erwinia chrysanthemi (recombinant)).
It’s been a rapid year of change for Coimmune Inc., which was incorporated only 12 months ago and now has FDA approval of an IND clearing the way for a phase IIb trial using CMN-001 to treat advanced metastatic renal cell carcinoma (mRCC).
